LONDON (Reuters) - British drugmaker GlaxoSmithKline, which paid $3 billion last year to settle charges that it gave misleading information on its medicines, said on Tuesday it would publish more of its clinical research data. When the company agreed to the fines last July, government officials called it the largest healthcare fraud case in U.S. history, involving Glaxo drugs such as the antidepressant Paxil and diabetes pill Avandia. Other firms have also reached settlement deals and the industry has come under growing pressure from campaign groups to release all their clinical trial data. ...
Source: news.yahoo.com
No comments:
Post a Comment